SLGL Stock — Sol-Gel Technologies Ltd.: Cash, EV, Pipeline

Share price

$60.00

Market cap

$196.4M

Cash

$54.8M

Enterprise value

$141.6M

Balance sheet

Cash	$54.8M
Debt	$0.0M
Net cash	$54.8M
Enterprise value	$141.6M
Basic shares	3.3M shares
Fully diluted shares	3.1M shares
Fully diluted market cap	$185.9M
Cash per share	$16.76

Cash figures as of 2026-03-25. Database snapshot: 2026-09-21.

Price history

Loading SLGL daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 12 - Dec 24	Patidegib Topical Gel	Phase 3	Gorlin Syndrome	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

SGT-610

Phase 3 · Active Modality: topical gel

Aliases patidegib 2% gel

Target hedgehog pathway

Indications

Gorlin Syndrome (BCC prevention) (Phase 3)

Status note Lead candidate. Phase III clinical study ongoing for prevention of new basal cell carcinomas in adults with Gorlin Syndrome. Orphan Drug Designation and Breakthrough Therapy designation.

SGT-210

Stage not disclosed · Active Modality: topical drug candidate

Aliases erlotinib

Target EGFR

Indications

not disclosed (Stage not disclosed)

Status note Topical erlotinib platform; development continuing. No stage or indication disclosed in 20-F.

Per-asset detail extracted from the 20-F filed 2026-03-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Patidegib Topical Gel
Lead indication	Gorlin Syndrome
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06050122	Phase 3	Active, not recruiting	Sponsor	Sol-Gel Technologies, Ltd.	—	Gorlin Syndrome	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Sol-Gel Technologies, Ltd. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

SLGL — Sol-Gel Technologies Ltd.